Interpace Biosciences, Inc. filed Amendment No. 1 to its Annual Report for the year ended December 31, 2025 to add Part III information on directors, executive compensation, security ownership, related-party matters and auditor fees that was originally expected to come from a proxy statement.
The filing details a five-member classified board, committee structures and independence determinations, and compensation for named executives. In 2025, CEO Thomas W. Burnell earned total compensation of $708,192, while CFO and COO Christopher McCarthy earned $468,265. Non-employee directors each received cash fees of up to $50,000.
The amendment also shows ownership concentration, with Ampersand 2018 Limited Partnership holding 13,861,386 shares (50.0%) and 1315 Capital II, L.P. holding 9,405,941 shares (34.0%) as of April 15, 2026, when 27,700,904 common shares were outstanding. Audit fees paid to EisnerAmper LLP were $320,250 for 2025. No new financial statements are included.
Interpace Biosciences reported Q4 2025 revenue of $9.2 million and full-year 2025 revenue of $38.7 million, both down versus 2024 but up versus thyroid-only pro forma comparisons. Income from continuing operations jumped to $22.8 million in Q4 and $25.0 million for the year, mainly from a one-time, non-cash tax-related accounting adjustment that released a deferred tax valuation allowance.
Thyroid testing remained the growth engine, with 2025 thyroid revenue up 21% and volume up 13% year-over-year. The company completed its shift to a thyroid-only diagnostics model, paid off its debt in Q4 2025, improved cash to $2.5 million, and moved stockholders’ equity from a deficit to a positive $22.4 million at year-end.
Interpace Biosciences, Inc. reported 2025 revenue of $38.7 million, down from $46.9 million in 2024. The decline was primarily driven by CMS ending reimbursement coverage for PancraGEN on April 24, 2025; Interpace stopped accepting specimens for the test after May 2, 2025. The company is concentrating on its thyroid tests, ThyGeNEXT and ThyraMIR v2. Gross profit was $24.1 million versus $29.9 million, and operating income was $4.1 million versus $8.1 million.
Net income was $24.6 million, compared with $6.7 million, largely reflecting a $21.2 million income tax benefit from a partial release of the valuation allowance. Adjusted EBITDA, a non-GAAP measure, was $5.434 million versus $8.699 million. Operating cash flow was $5.8 million compared with $4.6 million. Interpace paid the BroadOak term loan in full in November 2025 and reported $2.5 million of cash and cash equivalents at year-end.
1315 Capital II, L.P. reported acquisition or exercise transactions in a Form 4 filing for IDXG. The filing lists transactions totaling 9,424,941 shares at a weighted average price of $2.02 per share. Following the reported transactions, holdings were 9,405,941 shares.
Ampersand 2018 Limited Partnership, a 10% owner of Interpace Biosciences, Inc., reported converting preferred stock into common shares. On January 20, 2026, it converted 28,000 Series C Convertible Preferred shares into 13,861,386 shares of common stock.
The preferred shares had a stated value of $1,000 per share and a conversion price of $2.02 per common share, which determines how many common shares are issued on conversion. Following this transaction, the reporting holder owned 13,861,386 common shares directly and no remaining Series C preferred shares.
Interpace Biosciences, Inc. filed a current report describing preliminary, unaudited revenue for the year ended December 31, 2025, as outlined in a related press release.
The company also reported that all outstanding shares of its Series C Preferred Stock were converted into shares of its common stock, simplifying its equity structure. The press release dated January 20, 2026 is furnished as an exhibit to the report and is not treated as filed for purposes of liability under the Exchange Act.
Interpace Biosciences, Inc. reported that on December 3, 2025 it fully repaid its outstanding term loan facility with BroadOak Capital Partners before the loan’s scheduled maturity. This means the company has cleared that specific debt obligation earlier than required, which can simplify its capital structure and reduce future interest payments. The update was shared through a press release attached as an exhibit, providing more detail on the repayment and its context for the business.
Interpace Biosciences, Inc. (IDXG) furnished an 8-K under Item 2.02 announcing results of operations and financial condition for the quarter ended September 30, 2025. The company issued a press release, included as Exhibit 99.1, providing the full details.
The information in Item 2.02, including Exhibit 99.1, is being furnished and is not deemed “filed” for purposes of Section 18 of the Exchange Act. The filing also lists the Cover Page Interactive Data File as Exhibit 104.
Interpace Biosciences (IDXG) reported Q3 results. Revenue was $8.756 million, down 29% from $12.295 million a year ago, reflecting the April 2025 loss of Medicare coverage for PancraGEN. Gross profit was $5.439 million. Operating income from continuing operations was $1.145 million versus $2.301 million, and net income was $0.911 million versus $1.676 million.
For the nine months, revenue was $29.504 million, down from $34.515 million; operating income was $2.507 million versus $6.047 million; net income was $1.918 million versus $4.821 million. The company recorded $0.7 million in severance and related costs tied to its restructuring plan. Cash and cash equivalents were $1.423 million as of September 30, 2025, with current assets of $9.130 million and current liabilities of $5.945 million. The BroadOak term loan balance was $1.0 million (fair value $0.977 million) with the maturity extended to December 31, 2025 and interest-only payments beginning July 1, 2025. Shares outstanding were 4,428,539 as of November 7, 2025.
Adjusted EBITDA was $1.263 million in Q3 and $3.735 million year-to-date. Management notes continued focus on cost controls, receivable collections, and financing or strategic alternatives following the PancraGEN coverage change.